Fan et al. |
2013 |
China |
NAFLD + T2DM + obesity |
54.68 ± 12.14; 51.02 ± 10.10 |
68/49 |
RCT |
Exenatide |
Metformin |
12 weeks |
|
Shao et al. |
2014 |
China |
NAFLD + T2DM |
42 ± 3.2; 43 ± 4.1 |
30/30 |
RCT |
Exenatide + insulin glargine |
Insulin aspart + insulin glargine |
12 weeks |
|
Armstrong et al. |
2016 |
UK |
NASH with/without T2DM |
18–70 |
7/7 |
Double-blind, randomized, placebo-controlled trial |
Liraglutide |
Placebo |
12 weeks |
|
Armstrong et al. |
2016 |
UK |
NASH with/without T2DM |
50 ± 12; 50 ± 11 |
22/23 |
Multicentre, double-blinded, randomized, placebo-controlled phase 2 trial |
Liraglutide |
Placebo |
48 weeks |
|
Khoo et al. |
2017 |
Singapore |
NAFLD + obesity |
43.7 ± 10.4; 39.0 ± 8.1 |
12/12 |
Pilot randomized trial |
Liraglutide |
Diet + exercise |
26 weeks |
|
Wang et al. |
2017 |
China |
NAFLD + T2DM |
40–78; 41–75 |
49/49 |
RCT |
Exenatide + metformin |
Metformin |
12 weeks |
|
Feng et al. |
2017 |
China |
NAFLD + T2DM |
48.07 ± 12.59; 46.79 ± 9.68 |
29/14.5 |
Single-center, open-label, prospective, and randomized trial with parallel design |
Liraglutide |
Gliclazide |
24 weeks |
|
Feng et al. |
2017 |
China |
NAFLD + T2DM |
46.31 ± 12.32; 46.79 ± 9.68 |
29/14.5 |
Single-center, open-label, prospective, and randomized trial with parallel design |
Liraglutide |
Metformin |
24 weeks |
|
Tian et al. |
2018 |
China |
NAFLD + T2DM |
56.4 ± 8.4; 58.5 ± 7.6 |
75/52 |
RCT |
Liraglutide |
Metformin |
12 weeks |
|
Yan et al. |
2019 |
China |
NAFLD + T2DM |
45.7 ± 9.2; 43.1 ± 9.7 |
27/12 |
Randomized, open-label, active-controlled, parallel-group, multicenter trial |
Liraglutide |
Sitagliptin |
26 weeks |
|
Yan et al. |
2019 |
China |
NAFLD + T2DM |
45.6 ± 7.6; 43.1 ± 9.7 |
24/12 |
Randomized, open-label, active-controlled, parallel-group, multicenter trial |
Liraglutide |
Insulin glargine + metformin |
26 weeks |
|
Khoo et al. |
2019 |
Singapore |
NAFLD |
43.6 ± 9.9; 38.6 ± 8.2 |
15/15 |
Prospective randomized pilot study |
Liraglutide |
Diet + exercise |
26 weeks |